SEC Form 4 · accession 0001209191-16-156151

ChemoCentryx, Inc. · CCXI

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Chief Medical Officer

Period of report

Dec 16, 2016

Accepted (ET)

Dec 20, 2016 · 5:32 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001340652

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock	Dec 16, 2016	M	2,044	$6.90	A	55,638	D
Common Stock	Dec 16, 2016	S	2,044	$8.90	D	53,594	D
Common Stock	Dec 16, 2016	M	6,668	$6.00	A	60,262	D
Common Stock^F2	Dec 16, 2016	S	6,668	$8.6875	D	53,594	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (right to buy)^F4,F3	$6.00	Dec 16, 2016	M	4,168	D	Feb 17, 2009	Feb 17, 2019	Common Stock	4,168	10,000	D
Stock Option (right to buy)^F4,F3	$6.00	Dec 16, 2016	M	2,500	D	Jul 28, 2009	Jul 28, 2019	Common Stock	2,500	0	D
Stock Option (right to buy)^F4,F3	$6.90	Dec 16, 2016	M	2,044	D	Aug 4, 2011	Aug 4, 2021	Common Stock	2,044	37,221	D

F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2Reflects the weighted average sale price of the shares sold. The shares were sold in multiple trades at prices ranging from $8.50 to $9.00 per share, inclusive. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
F3As of December 16, 2016 and prior to this transaction, the option fully vested.
F4Not applicable.